Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity

被引:61
作者
Pereverzeva, E.
Treschalin, I.
Bodyagin, D.
Maksimenko, O.
Langer, K.
Dreis, S.
Asmussen, B.
Kreuter, J.
Gelperina, S.
机构
[1] Univ Frankfurt, Inst Pharmaceut Technol, D-60438 Frankfurt, Germany
[2] Russian Acad Med Sci, Gauze Inst Novel Antibiot, Moscow, Russia
[3] IM Sechenov Med Acad, Inst Mol Med, Moscow, Russia
关键词
cardiotoxicity; doxorubicin; human serum albumin; nanoparticles; poly(butyl cyanoacrylate); polysorbate; 80; rat; testicular toxicity;
D O I
10.1016/j.ijpharm.2007.01.031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A toxicological study of doxorubicin bound to poly(butyl cyanoacrylate) or human serum albumin nanoparticles coated with polysorbate 80 was performed in healthy rats. The doxorubicin formulations were injected at a therapeutic dose regimen (3 x 1.5 mg/kg with a 72 h interval), and the animals were followed up for 15 or 30 days. The overall result of this study suggests that the surfactant-coated nanoparticle formulations of doxorubicin have favorable toxicological profiles. Specifically, these formulations display a considerably reduced cardio- and testicular toxicity, as compared to a free drug. (c) 2007 Elsevier B.V. All rights reserved..
引用
收藏
页码:346 / 356
页数:11
相关论文
共 38 条
[1]   IDARUBICIN CARDIOTOXICITY - A RETROSPECTIVE STUDY IN ACUTE MYELOID-LEUKEMIA AND MYELODYSPLASIA [J].
ANDERLINI, P ;
BENJAMIN, RS ;
WONG, FC ;
KANTARJIAN, HM ;
ANDREEFF, M ;
KORNBLAU, SM ;
OBRIEN, S ;
MACKAY, B ;
EWER, MS ;
PIERCE, SA ;
ESTEY, EH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2827-2834
[2]   Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].
Batist, G ;
Ramakrishnan, G ;
Rao, CS ;
Chandrasekharan, A ;
Gutheil, J ;
Guthrie, T ;
Shah, P ;
Khojasteh, A ;
Nair, MK ;
Hoelzer, K ;
Tkaczuk, K ;
Park, YC ;
Lee, LW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454
[3]   Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery [J].
Calvo, P ;
Gouritin, B ;
Chacun, H ;
Desmaële, D ;
D'Angelo, J ;
Noel, JP ;
Georgin, D ;
Fattal, E ;
Andreux, JP ;
Couvreur, P .
PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1157-1166
[4]   TOXICITY OF POLYALKYLCYANOACRYLATE NANOPARTICLES .2. DOXORUBICIN-LOADED NANOPARTICLES [J].
COUVREUR, P ;
KANTE, B ;
GRISLAIN, L ;
ROLAND, M ;
SPEISER, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (07) :790-792
[5]   POLYCYANOACRYLATE NANOCAPSULES AS POTENTIAL LYSOSOMOTROPIC CARRIERS - PREPARATION, MORPHOLOGICAL AND SORPTIVE PROPERTIES [J].
COUVREUR, P ;
KANTE, B ;
ROLAND, M ;
GUIOT, P ;
BAUDUIN, P ;
SPEISER, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (05) :331-332
[6]  
COUVREUR P, 1986, POLYM NANOPARTICLES, P27
[7]   DOXORUBICIN AND DOXORUBICINOL PHARMACOKINETICS AND TISSUE CONCENTRATIONS FOLLOWING BOLUS INJECTION AND CONTINUOUS INFUSION OF DOXORUBICIN IN THE RABBIT [J].
CUSACK, BJ ;
YOUNG, SP ;
DRISKELL, J ;
OLSON, RD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (01) :53-58
[8]   DOXORUBICIN-LOADED NANOSPHERES BYPASS TUMOR-CELL MULTIDRUG RESISTANCE [J].
CUVIER, C ;
ROBLOTTREUPEL, L ;
MILLOT, JM ;
LIZARD, G ;
CHEVILLARD, S ;
MANFAIT, M ;
COUVREUR, P ;
POUPON, MF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (03) :509-517
[9]   Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs [J].
Danesi, R ;
Fogli, S ;
Gennari, A ;
Conte, P ;
Del Tacca, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (06) :431-444
[10]   Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action [J].
deVerdiere, AC ;
Dubernet, C ;
Nemati, F ;
Soma, E ;
Appel, M ;
Ferte, J ;
Bernard, S ;
Puisieux, F ;
Couvreur, P .
BRITISH JOURNAL OF CANCER, 1997, 76 (02) :198-205